Search Results for: XPO1

94 interactions involving XPO1 - exportin 1 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
CDC25A cell division cycle 25A
  • Transcription of E2F targets under negative control by DREAM complex
  • Polo-like kinase mediated events
  • Activation of ATR in response to replication stress
  • Ub-specific processing proteases
  • Cyclin E associated events during G1/S transition
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Cyclin A:Cdk2-associated events at S phase entry
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
CDC42 cell division cycle 42
  • GPVI-mediated activation cascade
  • EGFR downregulation
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • CD28 dependent Vav1 pathway
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • DCC mediated attractive signaling
  • Inactivation of CDC42 and RAC1
  • VEGFA-VEGFR2 Pathway
  • Myogenesis
  • Myogenesis
  • RHO GTPases activate KTN1
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAPK6/MAPK4 signaling
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • G beta:gamma signalling through CDC42
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOQ GTPase cycle
  • RHOG GTPase cycle
  • RHOJ GTPase cycle
  • RHOU GTPase cycle
  • RAC3 GTPase cycle
  • RHOV GTPase cycle
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Aminophosphonic acid-guanylate ester
  • Guanosine-5'-Diphosphate
CDCA4 cell division cycle associated 4
CDK1 cyclin dependent kinase 1
  • MAPK3 (ERK1) activation
  • E2F-enabled inhibition of pre-replication complex formation
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of the APC/C
  • Phosphorylation of Emi1
  • Condensation of Prophase Chromosomes
  • MASTL Facilitates Mitotic Progression
  • Resolution of Sister Chromatid Cohesion
  • Condensation of Prometaphase Chromosomes
  • Regulation of PLK1 Activity at G2/M Transition
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Initiation of Nuclear Envelope (NE) Reformation
  • Nuclear Pore Complex (NPC) Disassembly
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Depolymerization of the Nuclear Lamina
  • Anchoring of the basal body to the plasma membrane
  • MAPK6/MAPK4 signaling
  • Ovarian tumor domain proteases
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Degradation
  • Mitotic Prophase
  • G1/S-Specific Transcription
  • Cyclin A/B1/B2 associated events during G2/M transition
  • G2/M DNA replication checkpoint
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Transcriptional regulation by RUNX2
  • PKR-mediated signaling
  • Indirubin-3'-monoxime
  • Olomoucine
  • Hymenialdisine
  • SU9516
  • Alvocidib
  • Alsterpaullone
  • Seliciclib
  • AT-7519
  • Fostamatinib
  • Avotaciclib
CDKN1B cyclin dependent kinase inhibitor 1B
  • SCF(Skp2)-mediated degradation of p27/p21
  • AKT phosphorylates targets in the cytosol
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • RHO GTPases activate CIT
  • Constitutive Signaling by AKT1 E17K in Cancer
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates Cell Cycle
  • FLT3 Signaling
  • FOXO-mediated transcription of cell cycle genes
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Prostate cancer
CEBPA CCAAT enhancer binding protein alpha
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Acute myeloid leukemia (AML)
CHEK1 checkpoint kinase 1
  • Signaling by SCF-KIT
  • Activation of ATR in response to replication stress
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Transcriptional Regulation by E2F6
  • XL844
  • Enzastaurin
  • CHIR-124
  • N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE
  • 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE
  • 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID
  • (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL
  • 2-(cyclohexylamino)benzoic acid
  • 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE
  • (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE
  • 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE
  • (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL
  • 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA
  • (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE
  • 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE
  • 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA
  • 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID
  • 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL
  • (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL
  • (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL
  • N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE
  • (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC
  • 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE
  • 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE
  • 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL
  • 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL
  • REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE
  • 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine
  • N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE
  • 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE
  • [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone
  • 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol
  • 6-MORPHOLIN-4-YL-9H-PURINE
  • 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE
  • Prexasertib
  • Fostamatinib
  • LY-2608204
  • PF-477736
CHORDC1 cysteine and histidine rich domain containing 1
CIITA class II major histocompatibility complex transactivator
  • Interferon gamma signaling
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
  • Bare lymphocyte syndrome (BLS) type2
CRK CRK proto-oncogene, adaptor protein
  • ARMS-mediated activation
  • ARMS-mediated activation
  • Downstream signal transduction
  • Regulation of actin dynamics for phagocytic cup formation
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Regulation of signaling by CBL
  • FCGR3A-mediated phagocytosis
DDX3X DEAD-box helicase 3 X-linked
  • Neutrophil degranulation
DESI1 desumoylating isopeptidase 1
DR1 down-regulator of transcription 1
  • HATs acetylate histones
  • Formation of WDR5-containing histone-modifying complexes
E2F4 E2F transcription factor 4
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • G0 and Early G1
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • G1/S-Specific Transcription
  • Cyclin D associated events in G1
  • Cyclin A:Cdk2-associated events at S phase entry
E2F5 E2F transcription factor 5
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • G0 and Early G1
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • G1/S-Specific Transcription
  • Cyclin D associated events in G1
  • Cyclin A:Cdk2-associated events at S phase entry
EIF4E eukaryotic translation initiation factor 4E
  • ISG15 antiviral mechanism
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Transport of the SLBP independent Mature mRNA
  • Transport of the SLBP Dependant Mature mRNA
  • Transport of Mature mRNA Derived from an Intronless Transcript
  • mTORC1-mediated signalling
  • Deadenylation of mRNA
  • Deadenylation of mRNA
  • Translation initiation complex formation
  • Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
  • Ribosomal scanning and start codon recognition
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • M-decay: degradation of maternal mRNAs by maternally stored factors
  • Z-decay: degradation of maternal mRNAs by zygotically expressed factors
  • 7-methyl-GpppA
  • 7-methyl-7,8-dihydroguanosine-5'-diphosphate
  • 7-methyl-guanosine-5'-triphosphate
  • LY2275796
  • S-[(1-Hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate
EIF5A eukaryotic translation initiation factor 5A
  • Hypusine synthesis from eIF5A-lysine
ERF ETS2 repressor factor
  • Oncogene Induced Senescence
  • Oncogene Induced Senescence
FBXO7 F-box protein 7
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Parkinson's disease (PD)
FILNC1 FOXO induced long non-coding RNA 1

Page 2 out of 5 pages